Updated:
Zheshang Healthcare Capital
Zheshang Healthcare Capital deploys early-stage venture and growth equity into China's pharmaceutical and medical-device sectors from its base in Hangzhou.
Zheshang Healthcare Capital
Zheshang Healthcare Capital functions as a healthcare-dedicated investment manager based in Hangzhou, Zhejiang province. The firm deploys capital primarily at the seed, venture, and growth stages, targeting pharmaceutical, biotechnology, and medical-device enterprises across China. Its founding details and named principals are not publicly disclosed. The firm's investment strategy concentrates on equity positions in early-stage healthcare companies, spanning drug development platforms, medical-device manufacturers, and digital-health ventures. Zheshang Healthcare Capital participates through direct equity investments rather than operating as a fund-of-funds. Public record does not identify specific portfolio companies, co-investors, or disclosed fund vehicles as of the current research cycle. The Hangzhou headquarters places the firm at the center of one of China's most active provincial biotech corridors, alongside a dense ecosystem of contract research organizations and academic medical centers. Scale metrics, including assets under management and team headcount, remain undisclosed. Adjacent operating businesses or philanthropic structures tied to the firm have not been publicly documented. Structurally, the firm's sole focus on healthcare distinguishes it within a Chinese private-equity landscape crowded with multi-sector platforms. By concentrating exclusively on the life-sciences value chain, the firm's mandate aligns with a specialized sourcing model that relies on a deep regional clinical network in Zhejiang province rather than broad industry-agnostic origination.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Hangzhou
Corporate office
Hangzhou, Zhejiang, China
Sector focus
Frequently asked questions
What is Zheshang Healthcare Capital's investment mandate?
The firm invests across the healthcare spectrum, with a primary focus on early-stage pharmaceutical, biotechnology, and medical-device companies in China. The mandate includes seed, venture, and growth equity, executed through direct investments. Specific sub-sector weightings or exclusion lists have not been publicly disclosed.
Where does Zheshang Healthcare Capital source its deal flow?
Based on its Hangzhou headquarters, the firm likely draws proprietary deal flow from the Zhejiang province healthcare ecosystem, which hosts a concentration of biotech startups and contract research organizations. No explicit sourcing model has been described in available public records, though the geographic and sector specialization suggests a network-driven origination approach rather than a broad auction-based model.
Is Zheshang Healthcare Capital affiliated with a larger financial group?
The name 'Zheshang' references Zhejiang province mercantile heritage, but no specific parent entity or affiliated financial group has been publicly linked to the firm. Its operational independence relative to any larger investment platform is unconfirmed.
Does Zheshang Healthcare Capital invest outside China?
All available evidence points to a domestic China investment strategy. The firm's sector focus and location suggest it seeks to capitalize on local innovation in the life sciences. No cross-border investments or non-China office locations have been identified.
Who runs investment decisions at Zheshang Healthcare Capital?
Individual investment committee members or managing partners have not been publicly named. Given that principal identification is absent from all standard disclosures, the firm appears to operate with a low public profile regarding its leadership structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: